MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 61.74M shares outstanding
USMAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer.
The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Cristian Luput
Director
Jean-Manassé Theagène
Director
Jeffrey C. Himmelreich
Head of Finance and Principal Financial & Accounting Officer
Louie Ngar Yee
Director
Employees
13
Country
US
Sector
Healthcare
Website
maiabiotech.com
Loading congressional disclosures…
based on 61.74M shares outstanding
US30d Avg
698.69K
60d Avg
548.41K
90d Avg
516.87K
